Skip to content

Migraine in children and adolescents

TL;DR — Pediatric migraine is common, disabling and frequently under-recognized because attacks can be shorter, bilateral and described behaviourally rather than with adult symptom vocabulary (Abu-Arafeh 2024, PMID 38307664). Acute evidence supports ibuprofen, acetaminophen and selected triptan formulations; sumatriptan/naproxen and zolmitriptan nasal spray have high-confidence adolescent evidence for 2-hour pain freedom, while no acute treatment has high-confidence evidence for nausea/vomiting relief (Oskoui 2019, PMID 31413171). Prevention is dominated by high placebo response: CHAMP found no superiority of amitriptyline or topiramate over placebo and more adverse effects (Powers 2017, PMID 27788026). CBT added to amitriptyline reduced headache days and disability more than headache education plus amitriptyline in chronic migraine, showing that skills-based care can produce a clinically meaningful incremental effect (Powers 2013, PMID 24368463). School function, family context, mood, sleep and medication exposure are core outcomes, not optional context.

Age-dependent phenotype

Feature Children/adolescents Adult-shaped diagnostic risk
Duration May be 2–72 h; often shorter Four-hour lower bound misses cases
Location Bilateral frontotemporal pain common Overweighting unilateral pain
Description Behavioural avoidance of light/noise; limited symptom language Under-counting photo/phonophobia
Associated symptoms Nausea, vomiting and pallor can dominate Misclassification as GI illness
Aura Visual/sensory/language phenomena occur TIA rarer but epilepsy/structural differential remains
Disability School absence, impaired participation, family disruption Adult work-focused instruments miss burden

Diagnosis still rests on history and examination. The assessment includes development, family, school, peers and emotional context without reducing migraine to stress (Abu-Arafeh 2024, PMID 38307664). Pediatric reviews emphasize that shorter duration and bilateral location can be developmentally typical rather than exclusions (Hershey 2005, PMID 15928347). Pediatric migraine remains underdiagnosed when criteria or clinicians assume an adult phenotype (Winner 2007, PMID 17894928; Babineau 2012, PMID 22868546).

Differential diagnosis and testing

Most recurrent pediatric headache with a stable pattern and normal neurological examination does not require imaging. Concern rises with abrupt severe onset, progressive pattern, persistent focal deficit, papilledema, seizures, systemic illness, cancer/immunosuppression, positional/Valsalva pattern or age-incongruent features.

Presentation Main differential
Early-morning vomiting + papilledema Raised intracranial pressure/mass
Fever/neck stiffness CNS infection
Sudden maximal headache Hemorrhage/vascular cause
Brief stereotyped visual/motor events Focal seizure
New headache after concussion Post-traumatic headache and complications
Vertigo/episodic imbalance Vestibular migraine, BPPV, ear/central disorders

Pediatric vertigo often has multifactorial causes; quantitative vestibular testing is adjunctive, and migraine should not become a default label for every dizzy child (Peterson 2022, PMID 36165009).

Measuring burden

PedMIDAS adapts adult MIDAS to school, home and social function and demonstrated reliability/validity in a tertiary pediatric sample (Hershey 2001, PMID 11739822). It can underestimate disability on non-school days and during holidays because its items weight school loss (Heyer 2014, PMID 24708311).

Domain Minimum diary/assessment item
Frequency Headache days and migraine days
Function School missed, partial attendance and impaired days
Home/social Activities and responsibilities missed
Acute use Medicine and dose by day
Sleep Timing, duration, regularity and daytime sleepiness
Mood/anxiety Symptoms and safety, not assumptions from headache
Family Accommodation, conflict and practical treatment support

Clinical studies report increased anxiety/depression associations, but methods and referral bias vary; screening should identify treatable comorbidity rather than imply causation (Bruijn 2010, PMID 20603260). Obesity is associated with pediatric headache/migraine in much of the literature, but evidence is inconsistent and weight-focused counseling can stigmatize (Eidlitz Markus 2018, PMID 29725875).

Acute treatment

The AAN/AHS guideline recommends treating early, choosing route to attack characteristics and counselling about medication overuse. High-confidence evidence supports sumatriptan/naproxen oral, zolmitriptan nasal and some other triptan formulations for adolescent 2-hour pain freedom; ibuprofen is a first-line analgesic option (Oskoui 2019, PMID 31413171).

Option Evidence/use Key boundary
Ibuprofen Placebo-controlled pediatric benefit Weight-based dose; GI/renal/dehydration risk
Acetaminophen Common option with trial evidence Total daily dose and duplicate products
Sumatriptan/naproxen Adolescent efficacy NSAID and triptan contraindications
Zolmitriptan nasal Useful with nausea/rapid attacks Taste/nasal adverse effects
Other triptans Agent/route/age-specific evidence Adult class efficacy is not automatic pediatric approval
Antiemetic Symptom/route support Pediatric migraine-specific RCT evidence limited

Cochrane synthesis found ibuprofen and triptans effective in children/adolescents, but high placebo responses and few child-specific trials limited many comparisons (Richer 2016, PMID 27091010). An earlier pharmacologic review likewise identified few randomized pediatric trials and high placebo response as central interpretation problems (Evers 2013, PMID 23575981). FDA-submitted adolescent triptan trials often failed despite adult efficacy because endpoint timing, placebo response and design diluted separation (Sun 2013, PMID 23359002).

High placebo response

Placebo response in pediatric migraine is a composite of natural fluctuation, regression to mean, expectation, study attention, adherence to routine and diary effects. A meta-analysis of pediatric prophylaxis trials found few durable drug–placebo separations and emphasized short follow-up (Locher 2020, PMID 32040139).

High placebo response does not mean symptoms are imagined or that active treatment has no effect. It means the trial must distinguish pharmacological increment over a strong contextual intervention and that supportive care is itself consequential.

CHAMP and pharmacologic prevention

CHAMP randomized 361 children/adolescents aged 8–17 to amitriptyline, topiramate or placebo; the trial stopped early for futility. The ≥50% reduction endpoint occurred in 52% with amitriptyline, 55% with topiramate and 61% with placebo, with more adverse events in active groups (Powers 2017, PMID 27788026).

CHAMP finding Correct interpretation
Placebo response exceeded active arms numerically Neither drug showed incremental efficacy in this trial
All groups improved substantially Structured trial participation/context was powerful
Active harms were higher Net benefit was unfavourable for routine first use in similar participants
Individual trajectories differed Average null does not identify a responder biomarker

Trajectory analysis found heterogeneous response patterns across the 168-day treatment period, but post-hoc classes do not create a validated treatment selector (Reidy 2022, PMID 34404270).

The prevention guideline concluded evidence is insufficient for many drugs and emphasized shared decision-making about uncertainty, comorbidity and adverse effects (Oskoui 2019, PMID 31413170). A broader review similarly sets medication results beside presentation and disability rather than treating trial efficacy as the whole pediatric outcome (Kacperski 2018, PMID 30234648). Pediatric practice should not import adult network rankings without age-specific efficacy and safety.

CBT in chronic migraine

In 135 youth aged 10–17 with chronic migraine and PedMIDAS >20, CBT plus amitriptyline was compared with headache education plus amitriptyline. CBT produced larger reductions in headache days and disability, with benefits maintained during follow-up (Powers 2013, PMID 24368463).

Secondary analysis found more CBT participants reached ≤4 headache days/month, a clinically interpretable low-frequency target (Kroner 2016, PMID 26992129). Adherence analysis showed session attendance, homework and medication use are distinct behaviours; trial efficacy assumes access and participation (Kroon Van Diest 2017, PMID 28118256).

Because both arms received amitriptyline, the trial isolates the incremental value of CBT over education within that regimen. It does not prove amitriptyline itself was necessary, especially after CHAMP.

Lifestyle, school and family plan

Problem Practical control Outcome
Missed school Written return/quiet-space/medication plan Full/partial attendance
Irregular sleep Consistent schedule and sleep-disorder evaluation Sleep and headache days
Skipped meals/dehydration Feasible school access to food/water Attack timing and participation
Exercise avoidance Graded return and confidence Activity without excessive restriction
Family accommodation Support treatment without reinforcing total avoidance Independence and function
Exam stress Planned acute access and coping skills Completed school tasks

Disability can persist after frequency improves, so return to school and social activity needs an explicit rehabilitation goal. Conversely, forced attendance without rescue/support can worsen impairment.

Refractory and status presentations

There is no unified pediatric definition of intractable migraine and the live search through 2026-08-30 found no randomized comparative infusion pathway. The largest recent evidence was a retrospective 187-person cohort pairing a five-day IV DHE protocol with a preventive change; chronic-migraine headache days fell from 28.6 to 26.3/month, but simultaneous prevention and no control preclude attributing the change to DHE (Pavitt 2025, PMID 40301763). Many algorithms therefore still extrapolate from adults and expert consensus (Alqahtani 2021, PMID 34089140). Repeated emergency rescue without prevention, diagnosis review and school planning is a systems failure rather than a durable strategy.

New or prolonged deficits, dehydration, persistent vomiting and abrupt change require secondary-cause assessment. Status migrainosus is a duration/disability construct with sparse pediatric comparative treatment data.

Newer therapies

CGRP antibodies, gepants and devices developed for adults are moving into pediatric trials, but results, ages and approvals are product-specific. Reviews emphasize the lag created by pediatric development requirements and the danger of assuming adult safety/efficacy (Iannone 2022, PMID 35455026; VanderPluym 2023, PMID 37604658).

Long-term questions are sharper in youth: growth, puberty, reproductive exposure, cardiovascular development and decades of intermittent blockade. Access policies should distinguish evidence absence from evidence of ineffectiveness.

Transition to adult care

Transition should preserve headache history, failed adequate trials, adverse reactions, effective routes, school/work accommodations and reproductive counseling. Abrupt loss of pediatric supports at age cutoffs can worsen adherence and emergency use.

Open questions

  • Which trial design can reduce pediatric placebo separation problems without discarding contextual benefit? (Powers 2017, PMID 27788026; Locher 2020, PMID 32040139)
  • Can baseline trajectories or digital phenotypes predict which youth benefit from CBT, topiramate or newer targeted therapy? (Reidy 2022, PMID 34404270)
  • What are the long-term developmental and reproductive safety profiles of CGRP-pathway therapies started in adolescence? (VanderPluym 2023, PMID 37604658)
  • Which school-based interventions reduce disability independently of headache frequency? (Heyer 2014, PMID 24708311)
  • How should pediatric chronic migraine and medication overuse thresholds be validated against outcomes rather than adult consensus? (Orr 2024, PMID 38568493)

References

  1. Abu-Arafeh I, et al. Migraine in children and adolescents: assessment and diagnosis. Handb Clin Neurol. 2024. PMID 38307664
  2. Orr SL. Headache in children and adolescents. Continuum. 2024. PMID 38568493
  3. Winner P. Epidemiology and diagnosis of migraine in children. Curr Pain Headache Rep. 2007. PMID 17894928
  4. Babineau SE, Green MW. Headaches in children. Continuum. 2012. PMID 22868546
  5. Hershey AD, et al. PedMIDAS: development of a pediatric migraine disability questionnaire. Neurology. 2001. PMID 11739822
  6. Heyer GL, et al. PedMIDAS scoring underestimates disability on non-school days. Headache. 2014. PMID 24708311
  7. Bruijn J, et al. Psychopathology in children and adolescents with migraine: systematic review. Pediatrics. 2010. PMID 20603260
  8. Eidlitz Markus T, et al. Obesity and migraine in childhood. Curr Pain Headache Rep. 2018. PMID 29725875
  9. Peterson J, et al. Evaluation and management of paediatric vertigo. Curr Opin Otolaryngol Head Neck Surg. 2022. PMID 36165009
  10. Oskoui M, et al. Acute treatment of migraine in children and adolescents: guideline update. Neurology. 2019. PMID 31413171
  11. Richer L, et al. Drugs for acute treatment of migraine in children and adolescents. Cochrane Database Syst Rev. 2016. PMID 27091010
  12. Sun H, et al. Migraine therapeutics in adolescents: systematic analysis of triptan trials. JAMA Pediatr. 2013. PMID 23359002
  13. Wöber-Bingöl Ç. Pharmacological treatment of acute migraine in adolescents and children. Paediatr Drugs. 2013. PMID 23575981
  14. Oskoui M, et al. Pharmacologic treatment for pediatric migraine prevention: guideline update. Neurology. 2019. PMID 31413170
  15. Powers SW, et al. Amitriptyline, topiramate, and placebo for pediatric migraine. N Engl J Med. 2017. PMID 27788026
  16. Locher C, et al. Pharmacologic treatments for pediatric migraine prophylaxis: network meta-analysis. JAMA Pediatr. 2020. PMID 32040139
  17. Reidy BL, et al. Treatment response trajectories in CHAMP. Cephalalgia. 2022. PMID 34404270
  18. Powers SW, et al. CBT plus amitriptyline for pediatric chronic migraine. JAMA. 2013. PMID 24368463
  19. Kroner JW, et al. CBT plus amitriptyline reduces pediatric chronic migraine to ≤4 days/month. Headache. 2016. PMID 26992129
  20. Kroon Van Diest AM, et al. Treatment adherence in the CBT and amitriptyline trial. Clin J Pain. 2017. PMID 28118256
  21. Slater SK, et al. Migraine in children: presentation, disability and response to treatment. Curr Opin Pediatr. 2018. PMID 30234648
  22. Alqahtani MM, et al. Approach to pediatric intractable migraine. Curr Neurol Neurosci Rep. 2021. PMID 34089140
  23. Hershey AD. Pediatric migraine: recognition and treatment. J Am Osteopath Assoc. 2005. PMID 15928347
  24. Iannone LF, et al. Emerging pharmacological treatments for migraine in pediatrics. Life. 2022. PMID 35455026
  25. VanderPluym JH, et al. Treatments on the horizon for migraine in children and adolescents. Neurology. 2023. PMID 37604658
  26. Pavitt S, et al. Repetitive dihydroergotamine infusions with preventive adjustment in pediatric chronic headache. J Headache Pain. 2025. PMID 40301763